Eli Lilly shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-stage Crohn’s disease trial and struck a deal to develop new cancer-targeting medicines.
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnEli Lilly shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-stage Crohn’s disease trial and struck a deal to develop new cancer-targeting medicines.nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]